Dr. Kathleen Elizabeth Rodgers

Titus Family Department of Clinical Pharmacy and Pharmaceutical Economics and Policy

School of Pharmacy

University of Southern California, USA

Associate Professor



1984 Ph.D., University of California, Organophosphorus Immunotoxicity

1980 B.Sc., University of California, Cell Biology

Publications (selected)

  1. diZerega, G.S. and Rodgers, KE. The Peritoneum. Springer Verlag, 1992.
  2. diZerega, G.S. DeCherney A.H., Diamond M.P., Dunn R. C., Goldberg E. P., Haney A.F., Rock J.A., Tulandi T., and Rodgers K.E. Pelvic Surgery. Springer Verlag, 1997.
  3. diZerega, G.S. DeCherney A.H., Diamond M.P., Ellis H., Gomel V., Haney A.F., Holmdahl L., Rock J.A., Rodgers K.E., Thompson J. Peritoneal Surgery. Springer Verlag, 2000.
  4. Roks AJ, Rodgers K, Walther T. Effects of the renin angiotensin system on vasculogenesis-related progenitor cells. Curr Opin Pharmacol. 2011 Apr; 11(2): 162-74.
  5. Rodgers KE, Burleson FG, Burleson GR, Lewis KM, Wolfsegger MJ, and Redl H. A Two-Component Polyethylene Glycol Sealant as an Adhesion Prevention Device Does Not Influence Intraperitoneal Infection in a Refined Animal Model. American Journal of Obstetrics and Gynecology, 2010 Nov; 203(5): 494. e1-6.
  6. Eidenschink, L, diZerega, GS, Rodgers, KE, Bartlett, Loken, MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months, Cytometry Part B (Clinical Cytometry), 2011 82B: 18-25.
  7. Rodgers KE, Verco S, Bolton, LL, diZerega GS. Accelerated Healing of Diabetic Wounds by NorLeu3-Angiotensin II(1-7), Expert Opinion on Investigational Drugs, 2011 Nov; 20(11):1575-81. Epub 2011 Oct 6.
  8. Mordwinkin NM, Russell J, Burke AS, diZerega G, Louie SG, Rodgers KE. Toxicological and Toxicokinetic Analysis of Angiotensin (1-7) in Two Species, Journal of Pharmaceutical Sciences, 2012 Jan; 101(1): 373-380.
  9. Mordwinkin NM, Meeks CJ, Jadhav SS, Espinoza T, Roda N, DiZerega GS, Louie SG, Rodgers KE. Angiotensin-(1-7) administration reduces oxidative stress in diabetic bone marrow. Endocrinology, 153(5): 2189-97.
  10. Balingit, P; Armstrong, DG; Reyzelman, AM; Bolton, L; Verco, SJ; Rodgers, KE; diZerega, GS. Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Safety and Effectiveness of NorLeu3-A (1-7) in Treating Subjects with Diabetic Ulcers, Wound Repair and Regeneration, 20: 482-490.
  11. Rodgers KE, Espinoza TE, Roda N, Meeks CJ, Hill C, Louie SG, and diZerega GS. Accelerated Hematopoietic Recovery with Angiotensin-(1-7) after Total Body Radiation, International Journal of Radiation Biology, 2012 Jun; 88(6): 466-76.
  12. Rodgers KE. Hemocompatibility. In Encyclopedia of Toxicology, Volume 2, (Ed Phillip Wexler) Elseiver, Oxford UK, 2011.
  13. Rodgers KE. Idiopathic Environmental Intolerance. In Encyclopedia of Toxicology, Volume 3, (Ed Phillip Wexler) Elseiver, Oxford UK, 2011.
Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.